drugset
drugset / Trial / NCT00148122

A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer

NCT00148122 ↗

Phase 2 Completed 40 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness and side effects of a new combination and schedule of chemotherapy drugs in the treatment of head and neck cancer. Patients with advanced or recurrent head and neck cancer, which is untreatable by surgery or radiation therapy are eligible for this study. Standard treatment for advanced or recurrent head and neck cancer involves the use of chemotherapy.

Timeline

Start
2002-11
Primary completion
2008-08
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg Oral
Subject Docetaxel Small molecule 30 mg/m2 Intravenous

Indications

head and neck cancer